Physician profile
Frederick Wood
NPI 1164479473
$18,289.28
in general payments reported to CMS, 2019-2025
46 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,432 · 2020: $2,684 · 2021: $3,042 · 2022: $2,560 · 2023: $2,689 · 2024: $2,500 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,516 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,516.18 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,376.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,783.87 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,630.13 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,622.18 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,510.17 | 2019-2025 | |
| Amarin Pharma, INC. | $1,394.02 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,158.41 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $1,098.71 | 2019-2024 | |
| Amgen INC. | $724.12 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $597.25 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $553.15 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $539.13 | 2021-2024 | Verquvo |
| Abbott Laboratories | $364.95 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Cvrx, INC. | $271.90 | 2021-2023 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $243.66 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $239.68 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $215.55 | 2022-2023 | Optimizer |
| Azurity Pharmaceuticals, INC. | $211.72 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| Abiomed | $189.09 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $176.13 | 2024 | |
| Boston Scientific Corporation | $168.77 | 2022-2025 | Latitude Communicator Power Supply, Watchman Access System |
| Heartflow, INC. | $163.37 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $125.73 | 2023-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $95.45 | 2019-2020 | |
| Atricure, INC. | $87.01 | 2023 | |
| Tactile Systems Technology INC | $77.38 | 2019-2025 | Flexitouch Plus, Nimbl |
| Kiniksa Pharmaceuticals, LTD. | $69.35 | 2021-2022 | |
| Daiichi Sankyo INC. | $68.64 | 2024-2025 | Injectafer |
| Biotronik INC. | $68.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.44 | 2021-2025 | |
| Edwards Lifesciences Corporation | $59.05 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $47.33 | 2024 | Arcalyst |
| Cleerly, INC. | $38.22 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Bridgebio Pharma, INC. | $35.30 | 2025 | Attruby |
| Lilly USA, LLC | $32.33 | 2024 | Mounjaro |
| Kestra Medical Technology Services, INC. | $28.68 | 2025 | Assure Wcd |
| Irhythm Technologies, INC. | $25.13 | 2020 | |
| Inspire Medical Systems, INC. | $19.55 | 2025 | Inspire |
| Medtronic, INC. | $16.98 | 2023 | Linq II |
| Chiesi USA, INC. | $16.67 | 2025 | Juxtapid |
| Medtronic Vascular, INC. | $16.26 | 2020 | |
| Altathera Pharmaceuticals LLC | $15.96 | 2025 | Sotalol Hydrochloride |
| Ionis Pharmaceuticals, INC. | $14.02 | 2025 | Tryngolza |
| Bardy Diagnostics, INC. | $14.00 | 2020 | |
| Glaxosmithkline, LLC. | $13.67 | 2025 | Arexvy |
| Akcea Therapeutics, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.